NanoCube
Health

Improving diagnostic certainty in pancreatic cancer

THE GAP

Pancreatic cancer is often difficult to detect early because symptoms may be absent or nonspecific and there is no routine population screening. Once cancer is suspected, diagnosis can still require multiple investigations, and imaging or tissue sampling may not provide a definitive answer. This can leave patients and clinicians facing ongoing diagnostic uncertainty.

Explore Our Technology

Partner with Us

OUR APPROACH

NanoCube Health is developing a nanosensing and nanomotor platform with the aim of providing biopsy-like molecular insight without conventional tissue sampling. Our lead pancreatic cancer program is designed to support more confident diagnostic decisions when current investigations leave uncertainty, while also evaluating the same targeted platform for drug delivery.

The platform is progressing through preclinical validation, with future clinical studies required to establish diagnostic performance and therapeutic benefit.

Bringing molecular sensing to the disease itself

NanoCube’s platform is designed to interact with disease-associated biology in vivo, generate molecular signals close to their source and enable those signals to be read externally.

Website - Target, Sense, Interpret, Deli

One platform. Two paths
to patient impact

Website - Diagnostics and Therapeutics Overview.png

Building the evidence

Preclinical work has demonstrated target binding, measurable signal generation and nanomotor behaviour, with advanced 3D pancreatic cancer model work supporting progression into in vivo validation.